These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36587736)

  • 41. Revisiting colistin susceptibility testing: will adding calcium to Mueller-Hinton agar improve the detection of colistin resistance?
    Matuschek E; Brolund A; Karlsson Lindsjö O; Giske CG; Byfors S; Kahlmeter G
    Clin Microbiol Infect; 2021 Aug; 27(8):1172.e1-1172.e5. PubMed ID: 33901665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis.
    Lasko MJ; Huse HK; Nicolau DP; Kuti JL
    Ann Clin Microbiol Antimicrob; 2021 Jan; 20(1):9. PubMed ID: 33468149
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evaluation of susceptibility of multidrug-resistant Pseudomonas aeruginosa strains against ceftolozane/tazobactam].
    Prado-Montoro CD; Ruiz-Aragón J; Martínez Rubio C; García-Martín S; Freyre-Carrillo C; Rodríguez-Iglesias MA
    Rev Chilena Infectol; 2019 Oct; 36(5):551-555. PubMed ID: 31859795
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Karlowsky JA; Lob SH; DeRyke CA; Hilbert DW; Wong MT; Young K; Siddiqui F; Motyl MR; Sahm DF
    Antimicrob Agents Chemother; 2022 May; 66(5):e0018922. PubMed ID: 35491836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
    Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cefiderocol activity is compromised by acquired extended-spectrum oxacillinases in Pseudomonas aeruginosa.
    Vuillemin X; Da Silva M; Bour M; Landon C; Plésiat P; Jeannot K
    Int J Antimicrob Agents; 2023 Sep; 62(3):106917. PubMed ID: 37429451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in
    Kolesnik-Goldmann N; Seth-Smith HMB; Haldimann K; Imkamp F; Roloff T; Zbinden R; Hobbie SN; Egli A; Mancini S
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of Mueller-Hinton Agar.
    Potter RF; Wallace MA; Muenks CE; Alvarado K; Yarbrough ML; Burnham CD
    J Appl Lab Med; 2023 May; 8(3):523-534. PubMed ID: 36738243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the recommended colistin susceptibility testing methods with colistin gradient strips and semi-automated method for antimicrobial-resistant non-fermenting rods.
    Depka D; Mikucka A; Bogiel T; Gospodarek-Komkowska E
    J Microbiol Methods; 2020 May; 172():105905. PubMed ID: 32229263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa.
    Torres E; Villanueva R; Bou G
    J Med Microbiol; 2009 May; 58(Pt 5):625-629. PubMed ID: 19369524
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020.
    Liu PY; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Lee YL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
    J Microbiol Immunol Infect; 2022 Oct; 55(5):888-895. PubMed ID: 34521591
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli.
    Hindler JA; Humphries RM
    J Clin Microbiol; 2013 Jun; 51(6):1678-84. PubMed ID: 23486719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
    Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
    Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
    J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L; Dornbusch K; Hallander HO
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.
    Cercenado E; Cardenoso L; Penin R; Longshaw C; Henriksen AS; Pascual A
    J Glob Antimicrob Resist; 2021 Sep; 26():292-300. PubMed ID: 34274538
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.